DermBiont, Inc.

📍 Boston, United States🗓 Founded 2017👥 32 employees💰 Last funded Oct 2023
Biotechnology Research🌐 dermbiont.com
Website LinkedIn
DermBiont’s mission is to become the world’s leading precision dermatology company developing and commercializing targeted topical therapeutics that treat, cure, and prevent diseases. The company aims to impact the root causes of skin diseases through the development of targeted small molecule therapeutics with well-defined mechanisms of action and biotherapeutics that repair an imbalance of the microbiome. The company’s targeted topical therapeutics pipeline includes SM-020 for the treatment of seborrheic keratosis, SM-030 for the treatment of hyperpigmentation disorders of the skin, and DBI-001 & DBI-002 for the treatment of atopic dermatitis, tinea pedis, and onychomycosis. For more information, please visit www.dermbiont.com.
2
Total investors
1
Early stage
0
Mid stage
1
Late stage
2017
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Saudi Arabia
1
United States
1
Frequently asked questions
Who invested in DermBiont, Inc.?
DermBiont, Inc. has 2 investors on record on gritt.io, including 1 early-stage backers and 1 late-stage investors.
When did DermBiont, Inc. last raise funding?
The most recent investment in DermBiont, Inc. recorded on gritt.io was in October 2023.
When was DermBiont, Inc. founded?
DermBiont, Inc. was founded in 2017.
What industry is DermBiont, Inc. in?
DermBiont, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is DermBiont, Inc. based?
DermBiont, Inc. is headquartered in Boston, United States.